Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum

Astrid E. Greijer · Pien M. Delis-van Diemen · Remond J. A. Fijneman · Rachel H. Giles · Emile E. Voest · Victor W. M. van Hinsbergh · Gerrit A. Meijer

Abstract Expression of the transcription factor hypoxia-inducible factor 1 (HIF-1), which plays a key role in cellular adaptation to hypoxia, was investigated in normal colorectal mucosa (ten), adenomas (61), and carcinomas (23). Tissue samples were analyzed for HIF-1α, its upstream regulators, von Hippel–Lindau factor, AKT, and mammalian target of rapamycin (mTOR) and its downstream targets glucose transporter 1 (GLUT1), carbonic anhydrase IX, stromal-cell-derived factor 1 (SDF-1) by immunohistochemistry. In normal colorectal mucosa, HIF-1α was observed in almost all nuclei of surface epithelial cells, probably secondary to a gradient of oxygenation, as indicated by pimonidazole staining. The same staining pattern was present in 87% of adenomas. In carcinomas, HIF-1α was present predominantly around areas of necrosis (78%). Active AKT and mTOR, were present in all adenomas, carcinomas, and in normal colorectal mucosa. GLUT1 and SDF-1 were present in the normal surface epithelium of all adenoma cases, whereas in the carcinoma GLUT1 was located around necrotic regions and SDF-1 was present in all epithelial cells. In conclusion, HIF-1α appears to be physiologically expressed in the upper part of the colorectal mucosa. The present observations support that upregulation of HIF-1α and its downstream targets GLUT1 and SDF-1 in colorectal adenomas and carcinomas may be due to hypoxia, in close interaction with an active phosphatidylinositol 3-kinases–AKT–mTOR pathway.

Keywords HIF-1 · mTOR · SDF-1 · CA IX · Colon

Introduction

Colorectal carcinomas arise from normal epithelial cells of the colorectal mucosa through an adenoma stage. The transition from benign adenomas to malignant carcinomas, occurring in about 5% of all adenomas, is only beginning to be explored in appreciable detail. Biological changes involved in this process include important signaling pathways like the mammalian target of rapamycin (mTOR)–AKT pathway while recently also a role for hypoxia-driven signaling was shown [6, 14]. Both pathways are mediated by the transcription factor hypoxia-inducible factor 1 (HIF-1) as depicted in Fig. 1. HIF-1 is involved in cellular adaptation to hypoxia in solid tumors, including stimulation of angiogenesis and glycolysis [33]. HIF-1 consists of two subunits of which the β-subunit is constitutively expressed, whereas HIF-1α is regulated in particular by the oxygen level. Under normoxia, the HIF-1α protein is hydroxylated by prolyl hydroxylases [15, 16], which enables the von
Hippel–Lindau factor (VHL) to bind, resulting in ubiqui-
nation and rapid degradation by the proteosome [27]. HIF-
1α is overexpressed in many solid tumors [38] and its
presence has been correlated with, i.e., poor prognosis in
breast and colorectal cancer patients [4, 36]. Stromal
expression of hypoxia-regulated proteins is an adverse
prognostic factor in colorectal carcinomas.

High protein levels of HIF-1α are not only caused by
hypoxia but can also be induced by the absence of wild-
type protein 53, mutated VHL and other tumor suppressor
genes, as well as by activation of oncogenes like Her2 neu
c-erbB-2) [24]. In addition, growth factors play a role.
However, both hypoxia and signaling-mediated HIF-1
stimulation are mediated by the phosphatidylinositol 3-
kinase (PI3K)–AKT, and the mTOR pathway [8]. Interest-
ingly, both the serine–threonine protein kinase AKT as well
as mTOR have been suggested to play a role in an early
stage of colorectal carcinogenesis [2, 30]. Furthermore,
the presence of a non-hypoxic HIF-1 induction has also been
suggested, in colorectal adenomas [9].

Upon HIF-1 activation, multiple target genes become
transcriptionally active, including genes involved in anaer-
obic glycolysis, metabolism, and angiogenesis. This
includes glucose transporter 1 (GLUT1), which facilitates
cellular glucose uptake [11, 26] and the angiogene-
associated genes vascular endothelial growth factor and
stromal-cell-derived factor 1 (SDF-1) also known as CXCL12
[5]. Furthermore, carbonic anhydrase IX (CA IX) which is
prominently induced by hypoxia and is therefore considered
to be an intrinsic hypoxia marker, which correlates with
a chemical marker of hypoxia, pimonidazole [1, 17, 23, 28].
An additional function of CA IX is in the regulation of the
maintenance of the physiological equilibrium in normal
gastrointestinal tissue [31].

The present study aims to analyze the role HIF-1 in
normal colorectal mucosa, adenomas, and carcinomas. To
this end, the presence of HIF-1α as well as of its
downstream targets GLUT1, SDF-1, and CA IX were
analyzed in normal colon tissue, colorectal adenomas,
and carcinomas. To explore the possible cause of HIF-1 over-
expression, i.e., hypoxia or oncogenic stimulation, both the
presence of the chemical hypoxia marker pimonidazole and
of the HIF-1α upstream regulators, VHL, AKT, and
mTOR, were investigated.

Materials and methods

Tumor material

A total of 84 tissue samples were studied, consisting of 61
colorectal adenomas, 20 of which contained already a focus
of carcinoma and are therefore referred to as progressed
adenomas, in contrast to the 41 adenomas with dysplasia
only, which are referred to as nonprogressed adenomas. In
addition, 23 colorectal carcinomas were analyzed. These
samples were obtained from 75 patients, 37 of which were
female and 38 male. Mean age was 67.8 years (range 40–
89). Normal mucosa samples were obtained from the
resection margins of colectomy specimens from ten patients
with colorectal cancer. The study was approved by the
Institutional Review Board and was in accordance with
Dutch medical ethical guidelines.

Determination of hypoxic regions

Hypoxic regions in mouse tissues were visualized using the
Hydroxyprobe-1 kit (Chemicon International, Temecula,
CA, USA). These experiments were approved by the
animal experimentation ethics committee, according to
local and governmental regulations.

Briefly, mice were injected intravenously with pimonida-
zole (60-mg/kg body weight), which forms adducts from
reductively activated pimonidazole in hypoxic cells. Mice
were killed 90 min later by asphyxiation in CO2. The
Hydroxyprobe-1 monoclonal antibody was biotinylated
using D-biotinyl-ε-aminocaproic acid N-hydroxysuccinimide
ester (Boehringer Mannheim) and was used to stain
pimonidazole adducts in formalin-fixed paraffin-embedded tissues according to recommendations by the manufacturer.

Immunohistochemistry

Immunohistochemistry was performed on 4-μm-thick full-block consecutive sections. Slides were deparaffinized, followed by rehydration, and subsequently staining in batches with the antibodies described in Tables 1 and 2. HIF-1α staining was performed as described previously [3]. In brief, antigen retrieval was performed in antigen retrieval solution (DAKO, Glostrup, Denmark) for 45 min at 96°C. The primary antibody against HIF-1α was incubated at a dilution of 1:500 for 30 min at room temperature and the catalyzed signal amplification system (DAKO) was used for detecting HIF-1α staining.

For CA IX staining, no antigen retrieval step was used. Slides were incubated with a mouse primary antibody to CA IX in a 1:50 dilution for 30 min at room temperature. Detection was performed with the Envision+ system--horseradish peroxidase system for mouse primary antibodies (DAKO).

GLUT-1 staining was performed with a rabbit polyclonal anti-GLUT1 antibody clone A 3536, DAKO, dilution 1:400) without antigen retrieval and subsequently developed with a standard avidin–biotinylated peroxidase complex (DAKO).

Staining procedures for AKT and mTOR were identical. After antigen retrieval, endogenous peroxidase activity was blocked for 10 min in methanol containing 0.3% hydrogen peroxide. The AKT antibody (Phospho-Akt (Ser473)) and mTOR antibody (Phospho-mTOR (Ser2448)) both obtained from Cell Signaling (Danvers, MA, USA) were incubated overnight at 4°C in a 1:50 dilution and subsequently detected with a standard avidin–biotinylated peroxidase complex.

SDF-1 staining was performed similar to the AKT and mTOR staining, except for the secondary antibody, which was a goat anti-rabbit antibody in this case.

For VHL staining, antigen retrieval was performed and endogenous peroxidase was blocked as the AKT and mTOR staining. Primary antibody against VHL was incubated for 60 min by room temperature, followed by Powervision (Immunologic, Duiven, the Netherlands) incubation for 30 min and subsequently the staining was detected with diaminobenzidine (SIGMA FAST™ 3,3′-diaminobenzidine tablets, Sigma Aldrich, St. Louis, MO, USA).

Before the slides were mounted with cover slips, all sections were counterstained for 30 s with Mayer’s hematoxylin and dehydrated in 70%, 96%, and subsequently 100% ethanol and finally in xylene.

Evaluation and statistics

The intensity of the staining was compared between the normal mucosa, nonprogressed, progressed adenomas, and carcinomas and scored by two investigators. Staining intensity was scored in four classes (0 to 3) taking the negative control as a reference for score 0 and the positive control (clear cell renal adenocarcinomas (Grawitz tumor) as a reference for score 3). For HIF-1α, only nuclear staining was scored, for CA IX, membrane staining, and AKT and SDF-1 cytoplasmic staining, for mTOR predominantly cytoplasmic but also membrane staining was scored. Significance of differences between categories was analyzed by means of the Kruskal Wallis test. P-values<0.05 were considered to be significant.

Results

HIF-1α expression and its regulators hypoxia and VHL

In normal colorectal mucosa nine out of ten samples showed HIF-1α present in nuclei of the surface epithelium (Fig. 2). To evaluate whether hypoxia played a physiologic

| Antibody | Species | Company and institutes | Dilution | Incubation | Antigen retrieval | Detection |
|----------|---------|------------------------|----------|------------|------------------|----------|
| HIF-1α   | Mouse   | BD Pharmingen           | 1/500    | 30' RT     | WB TRS 97°C 45'  | CSA      |
| Akt      | Rabbit  | Cell Signaling          | 1/50     | o/n 4°C   | WB Citr 97°C 10' | ABC      |
| mTOR     | Rabbit  | Cell Signaling          | 1/50     | o/n 4°C   | WB Citr 97°C 10' | ABC      |
| VHL      | Mouse   | BD Pharmingen           | 1/100    | 60' RT    | WB Citr 97°C 20' | Powervision |
| CA IX    | Mouse   | Lab Harris              | 1/50     | 30' RT    | none             | Envision+ |
| Glut-1   | Rabbit  | DAKO                   | 1/400    | 60' RT    | WB Citr 97°C 20' | ABC      |
| SDF-1    | Mouse   | R&D systems             | 1/400    | o/n 4°C   | WB Citr 97°C 10' | ABC      |
| Hydroxyprobe-1 | Mouse | Chemicon International | 1/200   | 40'RT       | 0.01% pronase in PBS 40°C for 40' | ABC      |

BD Transduction laboratories, *Mab* monoclonal antibody, *PAb* polyclonal antibody, *RT* room temperature, *WB* water bath, *TRS* target retrieval solution (DAKO), *Citr* citrate buffer 10 mM pH 6.0, *CSA* catalyzed signal amplification system (DAKO), *ABC* avidin–biotinylated peroxidase complex, *Powervision* from immunologic R&D systems.
role in the induction of HIF-1α in normal colorectal mucosa, we used mice that were injected with pimonidazole, a chemical marker of hypoxia that can be visualized by immunohistochemistry. The presence of tissue hypoxia was demonstrated in the surface epithelium of normal colon mucosa of the treated mice (Fig. 3). The pattern of hypoxic cells in the normal colorectal mucosa in mice matched with the distribution of HIF-1α immunohistochemical staining in human colorectal mucosa.

The presence of HIF-1α in normal colorectal mucosa was compared with that in adenomas and carcinomas. Adenomas displayed HIF-1α expression in 53 of the 61 cases, predominantly at the surface, gradually decreasing towards the center of the adenomas. No differences were seen between nonprogressed and progressed adenomas (85% and 90%, respectively), as shown in Table 2. Of the carcinomas, 78% (n=18) were positive, showing nuclear staining of HIF-1α in epithelial tumor cells. In carcinomas, a decreasing gradient of HIF-1α staining was observed from necrotic areas towards the well-vascularized stroma. Besides the epithelial tumor cells, in carcinomas, inflammatory cells in the tumor-associated stroma, and in five cases B-cells in lymph follicles, were positive for HIF-1α.

Statistical analysis showed no significant differences in intensity of HIF-1α staining between normal mucosa, adenomas, and carcinomas.

VHL, the regulator of HIF-1α degradation, was also analyzed by means of immunohistochemistry (Fig. 2). VHL expression was observed in all epithelial cells in normal colorectal mucosa as well as in colorectal adenomas and carcinomas.

AKT and mTOR, oncogenic pathways regulating HIF-1α

To investigate whether, in addition to hypoxia, oncogenes and/or growth factors can contribute to the elevated HIF-1α, we studied the presence of phosphorylated forms of AKT and mTOR, which reflect an active state of the oncogene-driven pathway of HIF-1α activation. Low-intensity cytoplasmic staining for the active form of AKT (P-AKT) was seen in epithelial cells of normal mucosa in all tissues (Fig. 4). Positive staining was also seen in the smooth muscle cells of the muscularis propria and muscularis mucosae and in the walls of blood vessels.

### Table 2

|                | Nonprogressed Adenoma, n=41 | Progressed adenoma, n=20 | Adenocarcinoma, n=23 | Kruskal–Wallis test, P-value |
|----------------|-------------------------------|--------------------------|----------------------|-----------------------------|
| HIF-1          |                               |                          |                      |                             |
| Neg            | 6 (15)                        | 2 (10)                   | 5 (22)               | 0.8                         |
| +              | 0 (0)                         | 2 (10)                   | 1 (4)                |                             |
| ++             | 7 (17)                        | 3 (15)                   | 3 (13)               |                             |
| +++            | 28 (68)                       | 13 (65)                  | 14 (61)              |                             |
| AKT            |                               |                          |                      |                             |
| Neg            | 0 (0)                         | 0 (0)                    | 0 (0)                | 0.1                         |
| +              | 12 (29)                       | 7 (35)                   | 0 (0)                |                             |
| ++             | 11 (27)                       | 5 (25)                   | 10 (43)              |                             |
| +++            | 18 (78)                       | 8 (40)                   | 13 (57)              |                             |
| mTOR           |                               |                          |                      |                             |
| Neg            | 2 (5)                         | 0 (0)                    | 0 (0)                | 0.4                         |
| +              | 2 (5)                         | 3 (16)                   | 0 (0)                |                             |
| ++             | 12 (29)                       | 6 (32)                   | 7 (30)               |                             |
| +++            | 25 (61)                       | 10 (53)                  | 16 (70)              |                             |
| VHL            |                               |                          |                      |                             |
| Neg            | 0 (0)*                        | 1 (5)                    | 0 (0)                | 0.9                         |
| +              | 7 (18)                        | 0 (0)                    | 1 (4)                |                             |
| ++             | 12 (30)                       | 11 (55)                  | 11 (48)              |                             |
| +++            | 21 (53)                       | 8 (40)                   | 11 (48)              |                             |
| CA IX          |                               |                          |                      |                             |
| Neg            | 10 (24)                       | 4 (20)                   | 1 (4)                | 0.3                         |
| +              | 0 (0)                         | 0 (0)                    | 0 (0)                |                             |
| ++             | 1 (2)                         | 2 (10)                   | 2 (9)                |                             |
| +++            | 30 (73)                       | 14 (70)                  | 20 (87)              |                             |
| GLUT1          |                               |                          |                      |                             |
| Neg            | 0 (0)                         | 1 (5)                    | 0 (0)                | 0.02                        |
| +              | 8 (20)                        | 6 (30)                   | 0 (0)                |                             |
| ++             | 15 (37)                       | 4 (20)                   | 6 (26)               |                             |
| +++            | 18 (44)                       | 9 (45)                   | 17 (74)              |                             |
| SDF1           |                               |                          |                      |                             |
| Neg            | 8 (20)*                       | 7 (37)*                  | 0 (0)                | <0.005                      |
| +              | 4 (10)                        | 4 (21)                   | 0 (0)                |                             |
| ++             | 13 (33)                       | 2 (11)                   | 5 (22)               |                             |
| +++            | 15 (38)                       | 6 (32)                   | 18 (78)              |                             |

*One case not tested
adenomas, staining in epithelial cells was more intense, present throughout the neoplastic tissue, and observed in all cases. Staining patterns in adenocarcinomas were similar and also observed in all samples analyzed.

Active mTOR was only present as a cytoplasmatic staining; nuclear staining was not observed in any of the cases (Fig. 4). In normal mucosa, mTOR was detected in the surface epithelium in all tissues. Likewise, in adenoma samples, mTOR was expressed in the surface epithelium but also more diffusely throughout the adenomas. In adenocarcinomas, staining patterns were diffused across the whole tumor, but more intense expression was detected in areas surrounding necrosis. Higher levels of active mTOR were observed at the invasive front of the tumor. In the adenocarcinomas, besides the cytoplasmatic staining in some cells, a clear cellular membrane staining was observed. In all normal mucosa samples, adenomas, and carcinomas, mTOR was present, except for 5% of the nonprogressed adenomas, which were negative for mTOR (Table 2).

Expression of the HIF1 downstream targets Glut1 and SDF-1

To investigate to what extent downstream pathways were affected by HIF-1 upregulation, several HIF-1 target genes,
including GLUT1 and SDF-1, were analyzed in normal mucosa, adenomas, and adenocarcinomas. Expression of GLUT1, which is involved in glucose metabolism, was closely correlated with HIF-1α in all colon tissues analyzed. In normal colon mucosa, GLUT1 expression showed a gradient from the surface epithelium towards the basis of the crypts (Fig. 5). All normal tissues showed a positive GLUT1 staining. In nonprogressed adenomas, all cases showed GLUT1 expression compared to 95% of progressed adenomas. All adenocarcinomas (n=23) were positive for GLUT1 as well. Staining was localized at the cell membrane of epithelial cells in normal mucosa, adenomas, and adenocarcinomas (Fig. 5). Most intense staining was seen at the surface epithelium of adenomas and in the vicinity of necrosis in carcinomas. As to staining intensity, a significant difference was detected between the adenomas and the carcinomas (Table 2).

In normal colon tissue, SDF-1 expression was comparable to that of HIF-1α, i.e., it was detected in a gradient from the surface epithelium towards the basis of the crypts. However, in all colorectal adenomas and adenocarcinomas, intense SDF-1 expression was observed in the epithelial cells, which was located in the cell membrane and cytoplasm (Fig. 5). Because this epithelial SDF-1 expression was seen in all epithelial cells, it co-localized only partly with HIF-1α presence. In contrast to the comparable intensity of the HIF-1α staining in adenomas and adenocarcinomas, the SDF-1 staining intensity was much higher in adenocarcinomas than in the adenomas (Table 2). In addition to the epithelial expression of SDF-1, endothelial cells of blood vessels stained positive for SDF-1 (Fig. 6).

Expression of CA IX

CA IX was originally identified in gastrointestinal tissues and later recognized as a HIF-1 target gene in many tissues. In normal mucosa, the presence of CA IX actually did not co-localize with that of HIF-1α. CA IX was observed in the bottom parts of the crypts, i.e., in the proliferative compartment, in contrast to HIF-1α, which was present in the surface epithelium. Seventy percent of the normal tissues showed CA IX expression. In adenomas and particular adenocarcinomas, CA IX and HIF-1 expressions had more resemblance. In adenomas, CA IX was present in a more diffuse pattern throughout the whole adenoma, including the surface epithelium (Fig. 5). In the adenocarcinomas, CA IX showed a perinecrotic staining, mainly co-localizing with the HIF-1α expression.
Discussion

The present study demonstrates the presence of nuclear HIF-1α in the surface epithelium of normal colon and adenomas and in areas associated with peri-necrotic areas of colon adenocarcinoma. The data support a hypoxia-induced HIF-1 cascade, both in normal and neoplastic colorectal mucosa, as suggested by pimonidazole and HIF-1α patterns in association with GLUT1 and SDF-1 in normal colorectal mucosa and adenomas, as well as peri-necrotic HIF-1α and CA IX patterns in colorectal carcinomas. The occurrence of hypoxia around the surface epithelium was confirmed by pimonidazole staining of unaffected murine colon. Furthermore, hypoxia and the oncogenic activation of the AKT–mTOR pathway both contributed to HIF-1 expression in adenomas and adenocarcinomas. Moreover, the expression patterns of CA IX in normal mucosa and SDF-1 in neoplastic mucosa pointed to additional regulations independent from HIF-1.

The hypoxia–HIF-1 cascade

The presence of HIF-1α under physiological circumstances in the surface epithelium of normal colorectal mucosa observed in the present study may be due to the anaerobic environment in the lumen of the colon, which contributes to a relatively hypoxic state of especially this surface epithelium. Indeed, we observed accumulation of the chemical hypoxia marker pimonidazole particularly in the

---

**Fig. 5** Typical immunohistochemical staining patterns of HIF-1α, GLUT1, SDF-1, and CA IX in normal colon mucosa, colorectal adenomas, and adenocarcinomas. The downstream targets of HIF-1, i.e., SDF-1, GLUT1, and CA IX, have predominantly overlapping staining with the presence of HIF-1. However, in normal mucosa, CA IX is not expressed in the HIF-1α positive surface epithelium but is expressed in the basal of the crypts. In adenocarcinomas, SDF-1 is not only present in HIF-1α-positive cells but in all epithelial cells.

**Fig. 6** SDF-1 expression in epithelial and endothelial cells of normal detected by immunohistochemistry.
surface epithelium, indicating low oxygen levels [19]. The presence of pimonidazole showed a gradient towards the basis of the crypts, suggesting that the cause of hypoxia was indeed related to the anaerobic lumen. Apparently, the capillaries in the surface regions of the colon epithelium were unable to cope with the high oxygen demand of the tissue. This strongly suggests that these hypoxic areas may induce HIF-1α, which contributes to a sustained pressure on the stimulation of angiogenesis and glycolysis to adjust the energy levels of these cells.

Although immunohistochemical analysis of patient samples does not allow a formal analysis of functional relationships, it is highly likely that the HIF-1 detected in normal colorectal mucosa was transcriptionally active because HIF-1α was detected in the nuclei and the HIF-1 downstream targets GLUT1 and SDF-1 were present in the same regions where HIF-1α was found.

In 87% of colorectal adenomas, HIF-1α was present, showing staining predominantly in the nuclei of the surface epithelium. In colorectal adenocarcinomas, the presence of HIF-1α changes from the surface epithelium to epithelium cells surrounding regions of necrosis, indicating severe hypoxia. Presence of HIF-1α in the nuclei of epithelial cells went along with expression of the downstream targets GLUT1 and SDF1 in all different stages of the colon carcinogenesis.

In contrast to SDF-1 and GLUT1, the downstream target CA IX, known as a stringent hypoxia marker [35], did not co-localize with HIF-1α staining in normal colorectal mucosa. It should be noted that CA IX was originally described to have a role in maintaining the physiological equilibrium in the gastrointestinal tract. In fact, CA IX was more abundant in the basal half of the crypts, containing the proliferating compartment, rather than in the upper half of the mucosa where HIF-1α expression was observed. Indeed, co-localization of CA IX with Ki-67, a proliferation marker, has been found in colorectal cancer [31]. The lack of HIF-1α in the CA IX-positive regions indicates an HIF-1α-independent regulation of CA IX in normal colon epithelium. CA IX expression was reported to be also regulated by the transcription factor SP1 [18, 31].

Oncogene-dependent regulation of HIF-1

Oncogene-dependent regulation of HIF-1 can be mediated by the AKT-mTOR pathway [24, 39]. In the present study, in epithelium of all normal colorectal mucosa, a weak staining of P-AKT was observed, confirming data of Itoh et al. [14]. In all adenomas and adenocarcinomas analyzed, the active (phosphorylated) forms of AKT and mTOR were detected as well. Especially active mTOR showed co-localization with HIF-1α in normal tissue as well as in adenomas and adenocarcinomas. Co-localization of P-AKT with HIF-1α was less evident. Recently, in breast cancer, it has been shown that in the absence of P-AKT, only low levels of HIF-1α could be detected while in the presence of P-AKT high HIF-1α protein levels were observed [10]. In colorectal tumorigenesis, this regulation mechanism may be less relevant because staining was already observed in normal tissue. In addition, the presence of active AKT was not HIF-1 related because in adenocarcinomas P-AKT was present in a higher percentage of cells present than HIF-1α. The downstream target of AKT, mTOR, displayed comparable cellular expression patterns to HIF-1α in normal, adenomas, and carcinomas. This suggests that the AKT–mTOR–HIF-1α axis may be important in tumor growth and development as was seen in prostate epithelial cells [25].

Expression of VHL

An alternative mechanism that can lead to HIF-1α overexpression is loss of VHL expression. In normal colon mucosa, VHL is expressed, while in colorectal tumors VHL has been found to be lost or mutated in 11% of cases [7, 21]. Mutations in the VHL gene have been reported to result in cytoplasmic staining of HIF-1α in colorectal cancer in one study [22], while this could not be confirmed in another study of 80 patients [40]. Also in the present study, no cytoplasmic staining of HIF-1α was seen at all, and VHL expression was seen in all epithelial cells of normal mucosa, colorectal adenomas, and carcinoma.

Expression of SDF1

SDF-1 was investigated in the present study as a downstream target of HIF-1α [13, 32]. Surprisingly, epithelial cells showed much stronger SDF-1 expression than endothelial cells lining blood vessels. In addition, expression was not merely restricted to areas showing HIF-1α staining but was observed in all epithelial adenomas and adenocarcinomas. SDF-1 staining in tumors cells has also been reported in breast cancer patients [29] and in clear cell–renal cell carcinomas, in which HIF-1α is constitutively expressed [37]. The intense staining of the colon tumor cells suggests that SDF-1 not only has a function in attracting circulating progenitor cells towards the angiogenic areas [12]. Indeed, SDF-1 stimulates intestinal epithelial cell migration and enhances the integrity of the mucosal barrier [34].

The level of expression of SDF-1 might also play a role in tumorigenesis because it is related with prognosis in colorectal cancer. The presence of its coding mRNA and the mRNA of its receptor, CXCR4, have been shown to be a poor prognostic factor [20]. In tumor formation, SDF-1 may bear impact on the recruitment of various types of progenitor cells needed for enhanced growth of the tumor tissue [29]. Our study supports a role of SDF-1 in
carcinogenesis because SDF-1 staining becomes more intense with the progression of normal colon tissue toward carcinomas. However, future studies are needed to substantiate such role.

Conclusion

The common expression of HIF-1α in the surface epithelium of the colorectal mucosa suggests that HIF-1 may play a role in the physiology of normal colon tissue. HIF-1α presence does not appear to be related to progression of colorectal carcinogenesis in contrast to GLUT1 and SDF-1, which are expressed more intensely at later stages of this process.

Acknowledgements The authors thank Cristel Snijckers and Helma van den Berg for technical assistance and Prof. A.L. Harris for providing the CA IX antibody. This work was supported in part by the 1st AEGON International Scholarship in Oncology.

Conflict of interest statement We declare that we have no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Airley RE, Loncaster J, Raleigh JA, Harris AL, Davidson SE, Hunter RD, West CM, Stratford IJ (2003) GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer 104:85–91
2. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM (2003) Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc^-/-Delta716 Cdx2^-/- compound mutant mice. Nat Genet 35:13–330
3. Bos R, Zhong H, Hanrahan CF, Simons JW, van Diest PJ, van Der Wall E (2001) Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 93:309–314
4. Bos R, Van Der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, Van den Berg for technical assistance and Prof. A.L. Harris for providing the CA IX antibody. This work was supported in part by the 1st AEGON International Scholarship in Oncology. van Diest PJ, Clevers H, Voest EE (2006) Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene 25(21):3065–3070
8. Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15:807–826
9. Goethals L, Debuquoy A, Permeel C, Geboes K, Ectors N, De Schutter H, Penninckx F, McBride WH, Begg AC, Haustermans KM (2006) Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiat Oncol Biol Phys 65:246–254
10. Gort EH, Groot AJ, Verlaan I, Van Der Wall E, Shvarts A (2006) Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. Oncogene 25(45):6123–6127
11. Greijer A, Van Der Groep P, Kemming D, Shvarts A, Semenza G, Meijer G, Van De Wiel M, Belien J, van Diest P, van Der Wall E (2005) Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 206(3):391–304
12. Grunewald M, Avraham I, Dor Y, Bachar-Lustig E, Itin A, Yung S, Chimenti S, Landsman L, Abramovitch R, Keshet E (2006) VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 124:175–189
13. Heidemann J, Ogawa H, Raffiee P, Luger N, Maaser C, Domshche W, Binion DG, Dwinnell MB (2004) Mucosal angio genesis regulation by CXCR4 and its ligand CXCL12 expressed by human intestinal microvascular endothelial cells. Am J Physiol Gastrointest Liver Physiol 286:G1059–G1068
14. Itoh N, Somba S, Ito M, Takeda H, Kawata S, Yamakawa M (2002) Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 94:3127–3134
15. Ivan M, Kondo K, Yang H, Kim W, Viale J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr (2001) HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292:464–468
16. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gaskell SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472
17. Karhausen J, Furuta GT, Tomaszewski JE, Johnson RS, Colgan SJ, Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 292:468–472
18. Kaluz S, Kaluzova M, Stanbridge EJ (2003) Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia- responsive enhancer. Cancer Res 63:7066–7074
19. Kaluz S, Kaluzova M, Stanbridge EJ (2003) Expression of the hypoxia marker carbonic anhydrase IX is critically dependent on SP1 activity. Identification of a novel type of hypoxia- responsive enhancer. Cancer Res 63:917–922
20. Kim J, Takeuchi H, Lam ST, Turner RR, Wang HJ, Kuo C, Foshag L, Bilchik AJ, Hoon DS (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744–2753
21. Kuwai T, Kitadai Y, Tanaka S, Onogawa S, Matsutani N, Kaio E, Foshag L, Bilchik AJ, Hoon DS (2005) Chemokine receptor CXCR4 expression in colorectal cancer patients increases the risk for recurrence and for poor survival. J Clin Oncol 23:2744–2753
22. Kuwai T, Kitadai Y, Tanaka S, Hiyama T, Taninoto K, Chayama K (2004) Mutation of the von Hippel–Lindau (VHL) gene in human
colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha. Cancer Sci 95:149–153
23. Lal A, Peters H, St Croix B, Haroon ZA, Dewhirst MW, Strausberg RL, Kaanders JH, Der Kogel AJ, Riggins GJ (2001) Transcriptional response to hypoxia in human tumors. J Natl Cancer Inst 93:1337–1343
24. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. Her2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (hif-1alpha) synthesis: novel mechanism for hif-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21:3995–4004
25. Majumder PK, Sellers WR (2005) Akt-regulated pathways in prostate cancer. Oncogene 24:7465–7474
26. Manalo DJ, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, Garcia JG, Semenza GL (2005) Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 105:659–669
27. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, Ratcliffe PJ (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271–275
28. Olive PL, Aquino-Parsons C, MacPhail SH, Liao SY, Raleigh JA, Lerman MI, Stanbridge EJ (2001) Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. Cancer Res 61:8924–8929
29. Orimo A, Gupta PB, Sgroi DC, Arentzana-Seisdedos F, Delanauy T, Naeem R, Carey VI, Richardson AL, Weinberg RA (2005) Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121:335–348
30. Roy HK, Oltusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT, Smyrk TC (2002) AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis 23:201–205
31. Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastorekova S, Pastorek J, Kairaluoma MI, Karttunen TJ (1998) Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153:279–285
32. Schrader AJ, Lechner O, Templin M, Dittmar KE, Machens S, Mengel M, Probst-Kepper M, Franzke A, Wollensak T, Gatzlaff P, Atzpodien J, Buer J, Lauber J (2002) CXCR4/CXCL12 expression and signalling in kidney cancer. Br J Cancer 86:1250–1256
33. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732
34. Smith JM, Johansen PA, Wendt MK, Binion DG, Dwinell MB (2005) CXCL12 activation of CXCR4 regulates mucosal host defense through stimulation of epithelial cell migration and promotion of intestinal barrier integrity. Am J Physiol Gastrointest Liver Physiol 288:G316–G326
35. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibta A, Wilson GD, Turley H, Talks KL, Maxwell PH, Pugh CW, Ratcliffe PJ, Harris AL (2000) Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60:7075–7083
36. Yoshimura H, Dhar DK, Kohno H, Kubota H, Fujii T, Ueda S, Kinugasa S, Tachibana M, Nagasue N (2004) Prognostic impact of hypoxia-inducible factors 1alpha and 2alpha in colorectal cancer patients: correlation with tumor angiogenesis and cyclooxygenase-2 expression. Clin Cancer Res 10:8554–8560
37. Zaggag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA, Melamed J, Semenza GL (2005) Stromal cell-derived factor-1 alpha and CXCR4 expression in hemangioblastoma and clear cell-rena cell carcinoma: von Hippel–Lindau loss-of-function induces expression of a ligand and its receptor. Cancer Res 65:6178–6188
38. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zaggag D, Buechler P, Isaacs WB, Semenza GL, Simons JW (1999) Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59:5830–5835
39. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, Semenza GL (2000) Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60:1541–1545
40. Zhuang Z, Emmert-Buck MR, Roth MJ, Gnarra J, Linehan WM, Liotta LA, Lubensky IA (1996) von Hippel–Lindau disease gene deletion detected in microdissected sporadic human colon carcinoma specimens. Hum Pathol 27:152–156